SyntekaBio, Inc. announced that it has received KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation,KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors
November 30, 2021
Share
On November 30, 2021, SyntekaBio, Inc. closed the transaction.
Syntekabio,Inc. is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs.
SyntekaBio, Inc. announced that it has received KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation,KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors
SYNTEKABIO, INC. 